Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients

Clinical Immunology

Volumn 139, Issue 2, 2011, Pages 122-132

  Siedlar, Maciej ^a   Strach, Magdalena ^b   Bukowska Strakova, Karolina ^a   Lenart, Marzena ^a   Szaflarska, Anna ^a   Weglarczyk, Kazimierz ^a   Rutkowska, Magdalena ^a   Baj Krzyworzeka, Monika ^a   Pituch Noworolska, Anna ^a   Kowalczyk, Danuta ^a   Grodzicki, Tomasz ^b   Ziegler Heitbrock, Loems ^c,d   Zembala, Marek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

CD14+CD16++ monocytes; CD32B; Common variable immunodeficiency; Intravenous immunoglobulins

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MALE; MONOCYTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD14; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; GPI-LINKED PROTEINS; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOPHENOTYPING; INTERLEUKIN-10; INTERLEUKIN-12; KINETICS; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79954535492     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.01.002     Document Type: Article

References (43)

1. Zembala M., Uracz W., Ruggiero I., Mytar B., Pryjma J. Isolation and functional characteristics of FcR+ and FcR- human monocyte subsets. J. Immunol. 1984, 133:1293-1299.
2. Passlick B., Flieger D., Ziegler-Heitbrock H.W.L. Identification and characterization of novel monocyte subpopulation in human peripheral blood. Blood 1989, 74:2527-2534.
3. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 2007, 81:584-592.
4. Steppich B., Dayyani F., Gruber R., Lorenz R., Mack M., Ziegler-Heitbrock H.W.L. Selective mobilization of CD14(+)CD16(+) monocytes by exercise. Am. J. Physiol. Cell Physiol. 2000, 279:C578-C586.
5. Belge K.U., Dayyani F., Horelt A., Siedlar M., Frankenberger M., Frankenberger B., Espevik T., Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. 2002, 168:3536-3542.
6. Szaflarska A., Baj-Krzyworzeka M., Siedlar M., Weglarczyk K., Ruggiero I., Hajto B., Zembala M. Antitumor response of CD14+/CD16+ monocyte subpopulation. Exp. Hematol. 2004, 32:748-755.
7. Serbina N.W., Cherny M., Shi C., Bleau S.A., Collins N.H., Young J.W., Pamer E.G. Distinct responses of human monocyte subsets to Aspergillus fumigatus conidia. J. Immunol. 2009, 183:2678-2687.
8. Ziegler-Heitbrock H.W., Fingerle G., Ströbel M., Schraut W., Stelter F., Schütt C., Passlick B., Pforte A. The novel subset of CD14/CD16 blood monocytes exhibits features of tissue macrophages. Eur. J. Immunol. 1993, 23:2053-2058.
9. Randolph G.J., Sanchez-Schmitz G., Liebman R.M., Schäkel K. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 2002, 196:517-527.
10. Fingerle G., Pforte A., Passlick B., Blumensteein M., Strobel M., Ziegler-Heitbrock H.W. The novel subset of CD14/CD16 blood monocytes is expanded in sepsis patients. Blood 1993, 82:3170-3176.
11. Fingerle-Rowson G., Angstwurm M., Andreesen R., Ziegler-Heitbrock H.W. Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy. Clin. Exp. Immunol. 1998, 112:501-506.
12. Dayyani F., Belge K.U., Frankenberger M., Mack M., Berki T., Ziegler-Heitbrock L. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J. Leukoc. Biol. 2003, 74:33-39.
13. Emminger W., Zlabinger G.J., Fritsch G., Urbanek R. CD14(dim)/CD16(bright) monocytes in hemophagocytic lymphohistiocytosis. Eur. J. Immunol. 2001, 31:1716-1719.
14. Takeyama N., Yabuki T., Kumagai T., Takagi S., Takamoto S., Noguchi H. Selective expansion of the CD14(+)/CD16(bright) subpopulation of circulating monocytes in patients with hemophagocytic syndrome. Ann. Hematol. 2007, 86:787-792.
15. Katayama K., Matsubara T., Fujiwara M., Koga M., Furukawa S. CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin. Exp. Immunol. 2000, 121:566-570.
16. Mizuno K., Toma T., Tsukiji H., Okamoto H., Yamazaki H., Ohta K., Ohta K., Kasahara Y., Koizumi S., Yachie A. Selective expansion of CD16highCCR2- subpopulation of circulating monocytes with preferential production of haem oxygenase (HO)-1 in response to acute inflammation. Clin. Exp. Immunol. 2005, 142:461-470.
17. Chen C.J., Huang Y.C., Jaing T.H., Hung I.J., Yang C.P., Chang L.Y., Lin T.Y. Hemophagocytic syndrome: a review of 18 pediatric cases. J. Microbiol. Immunol. Infect. 2004, 37:157-163.
18. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., Shulman S.T., Bolger A.F., Ferrieri P., Baltimore R.S., Wilson W.R., Baddour L.M., Levison M.E., Pallasch T.J., Falace D.A., Taubert K.A. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110:2747-2771.
19. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin. Immunol. 1999, 93:190-197.
20. Veri M.C., Gorlatov S., Li H., Burke S., Johnson S., Stavenhagen J., Stein K.E., Bonvini E., Koenig S. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007, 121:392-404.
21. Daëron M. Fc receptor biology. Annu. Rev. Immunol. 1997, 15:203-234.
22. Heimbeck I., Hofer T.F., Eder C., Wright A.K., Frankenberger M., Marei A., Boghdadi G., Scherberich J., Ziegler-Heitbrock L. Standardized single-platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females. Cytometry 2010, 77:823-830.
23. Galatiuc C., Gherman M., Metes D., Sulica A., DeLeo A., Whiteside T.L., Herberman R.B. Natural killer (NK) activity in human responders and nonresponders to stimulation by anti-CD16 antibodies. Cell. Immunol. 1995, 163:167-177.
24. Aukrust P., Frøland SS S.S., Müller F. Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features. Clin. Exp. Immunol. 1992, 89:211-216.
25. Reipert B.M., Stellamor M.T., Poell M., Ilas J., Sasgary M., Reipert S., Zimmermann K., Ehrlich H., Schwarz H.P. Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang. 2008, 94:334-341.
26. Altznauer F., von Gunten S., Späth P.P., Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J. Allergy Clin. Immunol. 2003, 112:1185-1190.
27. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., Kaveri S.V. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J. Immunol. 1998, 161:3781-3790.
28. Zhao C., Zhang H., Wong W.C., Sem X., Han H., Ong S.M., Tan Y.C., Yeap W.H., Gan C.S., Ng K.Q., Koh M.B., Kourilsky P., Sze S.K., Wong S.C. Identification of novel functional differences in monocyte subsets using proteomic and transcriptomic methods. J. Proteome Res. 2009, 8:4028-4038.
29. Pearse R.N., Kawabe T., Bolland S., Guinamard R., Kurosaki T., Ravetch J.V. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 1999, 10:753-760.
30. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., Walker E.U., Manz R.A., Tarlinton D.M., Smith K.G. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 2007, 8:419-429.
31. Hume D.A. Macrophages as APC and the dendritic cell myth. J. Immunol. 2008, 181:5829-5835.
32. Eslick J., Scatizzi J.C., Albee L., Bickel E., Bradley K., Perlman H. IL-4 and IL-10 inhibition of spontaneous monocyte apoptosis is associated with Flip upregulation. Inflammation 2004, 28:139-145.
33. Katayama K., Matsubara T., Fujiwara M., Koga M., Furukawa S. CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin. Exp. Immunol. 2000, 121:566-570.
34. Frankenberger M., Sternsdorf T., Pechumer H., Pforte A., Ziegler-Heitbrock H.W. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood 1996, 87:373-377.
35. Wu K.H., Wu W.M., Lu M.Y., Chiang B.L. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr. Allergy Immunol. 2006, 17:60-68.
36. Ichiyama T., Ueno Y., Hasegawa M., Niimi A., Matsubara T., Furukawa S. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:428-433.
37. Gupta M., Noel G.J., Schaefer M., Friedman D., Bussel J., Johann-Liang R. Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 2001, 21:193-199.
38. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
39. Zhang Y., Liu S., Liu J., Zhang T., Shen Q., Yu Y., Cao X. Immune complex/Ig negatively regulate TLR4-triggered inflammatory response in macrophages through Fc gamma RIIb-dependent PGE2 production. J. Immunol. 2009, 182:554-562.
40. Veri M.C., Gorlatov S., Li H., Burke S., Johnson S., Stavenhagen J. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 2007, 121:392-404.
41. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl Acad. Sci. USA 2008, 105:19571-19578.
42. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
43. Galeotti C., Bayry J., Kone-Paut I., Kaveri S.V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun. Rev. 2010, 9:441-448.